Study focus area

OUR STUDIES

RETENTION AND REENGAGEMENT IN CARE OF PEOPLE LIVING WITH HIV (PLHIV) THROUGH PHYSICIAN AND MEDIA DELIVERED U=U RETENTION IN CARE EDUCATION IN PHOENIX, ARIZONA

Background

For many PLHIV and their partners, the Undetectable = Untransmittable (U=U) message is a fundamental paradigm shift that provides an unprecedented opportunity to improve lives of people living with HIV, dismantle HIV stigma, and encourage people to start and stay on treatment for their health and the health of their sexual partners. No previous research study focused on the clinical assessment of the dissemination of the U=U messaging was known to date whilst anecdotal data continues to accumulate, and clinical guidelines call for its integration into clinical discussions. The assessment of the intended study implementation explores best practices and lessons learned pertaining related to implementing such a study

u = u ndetectable

Design

To aid future research on the effectiveness of the U=U message campaign as a clinical intervention, the aim of the intended study assessment is to document the clinics’ experience and lessons learned of running hybrid type 1 research to evaluate the effectiveness of a clinic-delivered media campaign of the U=U message.

Primary objectives

  • Assess the barriers and facilitators associated with implementing a U=U campaign intervention 
  • Provide recommended best practices for Increasing patient provider communication around U=U to improve patient retention in care

Challenges and Lessons Learned

A key learning from conducting this study was that it is not feasible to combine the initial HIV-related assessments and activities required for newly diagnosed HIV patients with substantially time-consuming baseline study visit-related forms and procedures. An additional challenge for this study was the high levels of demand from HIV patients. Both clinics included in this study had an extremely high volume of HIV patients (e.g., one clinic database includes ~4,000 patients). Due to this demand, both clinics were resource-challenged, making it infeasible to perform all the required study-related activities. Results are expected to be published by the end of 2022.

Collaborators

Dr. Thanes Vanig
Dr. Ann Khlasa

Setting

Two clinical sites in the Phoenix, Arizona region

Location

USA

Duration

April 2019 – Oct 2020

Category

Health Related Quality of Life

ViiV study lead and contact

Tammeka Evans,

Director of Global Public Health and Innovation

Contact

RELATED STUDIES

USA

In an effort to increase retention in care, this study aims to evaluate the effectiveness of phone calls from primary caregiver to retain HIV positive patients in care and within the same health care system.

USA

This study aims to determine the reach of the U=U message and better understand the context for implementation across different audiences using social media and other virtual approaches implemented by community ambassadors.

USA

As part of this project, financial incentives were used to engage and retain people living with HIV with the goal of contributing to viral suppression in the Baton Rouge, LA area.

Our partnerships

Our partnerships

We are proud to partner with multiple organizations that work to prevent HIV and improve the lives of people who live with HIV.

Find out more

NP-GBL-HVU-WCNT-210050 | March 2022

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.